Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins